14 insiders reported 69 Form 4 transactions for Tango Therapeutics, Inc. (TNGX) over the past 18 months (most recent 2026-07-02). Recent activity: Crystal Adam (President, R&D) Buy 27,000 shares, Crystal Adam (President, R&D) Sell 19,629 shares, Crystal Adam (President, R&D) Sell 7,371 shares, Azelby Robert (Director) Buy 5,740 shares, Calhoun Lesley Ann (Director) Buy 4,000 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Crystal Adam | President, R&D | Buy | 27,000 | $140,400 |
| 2026-07-02 | Crystal Adam | President, R&D | Sell | 19,629 | $575,962 |
| 2026-07-02 | Crystal Adam | President, R&D | Sell | 7,371 | $222,946 |
| 2026-06-23 | Azelby Robert | Director | Buy | 5,740 | $0 |
| 2026-06-08 | Calhoun Lesley Ann | Director | Buy | 4,000 | $0 |
| 2026-06-08 | Lee Sung | Director | Buy | 570 | $0 |
| 2026-06-08 | Rothenberg Mace | Director | Buy | 4,000 | $0 |
| 2026-06-08 | Ketchum John B | Director | Buy | 4,000 | $0 |
| 2026-06-03 | Crystal Adam | President, R&D | Buy | 27,000 | $140,400 |
| 2026-06-03 | Crystal Adam | President, R&D | Sell | 6,140 | $136,627 |
| 2026-06-03 | Crystal Adam | President, R&D | Sell | 20,860 | $480,944 |
| 2026-05-01 | Lee Sung | Director | Buy | 12,300 | $0 |
| 2026-04-16 | Crystal Adam | President, R&D | Buy | 38,460 | $199,992 |
| 2026-04-16 | Crystal Adam | President, R&D | Sell | 38,460 | $961,500 |
| 2026-04-02 | Crystal Adam | President, R&D | Buy | 27,000 | $140,400 |
| 2026-04-02 | Crystal Adam | President, R&D | Sell | 27,000 | $572,478 |
| 2026-03-27 | Crystal Adam | President, R&D | Buy | 12,000 | $62,400 |
| 2026-03-27 | Crystal Adam | President, R&D | Sell | 12,000 | $241,320 |
| 2026-03-09 | Crystal Adam | President, R&D | Sell | 20,251 | $303,765 |
| 2026-02-27 | Crystal Adam | President, R&D | Sell | 54,345 | $693,986 |
| 2026-02-04 | Crystal Adam | President, R&D | Buy | 47,460 | $0 |
| 2026-02-04 | Crystal Adam | President, R&D | Sell | 18,251 | $223,757 |
| 2026-02-04 | Crystal Adam | President, R&D | Sell | 201 | $2,593 |
| 2026-02-04 | Beckman Daniella | Chief Financial Officer | Buy | 44,330 | $0 |
| 2026-02-04 | Beckman Daniella | Chief Financial Officer | Sell | 10,204 | $125,101 |
Source: SEC Form 4 filings · as of 2026-07-02